Fatty-acid amide hydrolase 1

• The (endo)cannabinoid signaling in female reproduction: What are the latest advances? (24 Sep 2024)
  
• Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis (24 Sep 2024)
  
• Saturated Cannabinoids: Update on Synthesis Strategies and Biological Studies of These Emerging Cannabinoid Analogs (02 Sep 2024)
  
• Potential of CBD Acting on Cannabinoid Receptors CB1 and CB2 in Ischemic Stroke (02 Sep 2024)
  
• Motifs in Natural Products as Useful Scaffolds to Obtain Novel Benzo[d]imidazole-Based Cannabinoid Type 2 (CB2) Receptor Agonists (02 Sep 2024)
  
• Molecular Advances on Cannabinoid and Endocannabinoid Research (02 Sep 2024)
  
• Hemp Seed Oil Inhibits the Adipogenicity of the Differentiation-Induced Human Mesenchymal Stem Cells through Suppressing the Cannabinoid Type 1 (CB1) (02 Sep 2024)
  
• Fatty Acid Amides Suppress Proliferation via Cannabinoid Receptors and Promote the Apoptosis of C6 Glioma Cells in Association with Akt Signaling Pathway Inhibition (02 Sep 2024)
  
• Exploring the Therapeutic Potential of Cannabinoid Receptor Antagonists in Inflammation, Diabetes Mellitus, and Obesity (02 Sep 2024)
  
• Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality (02 Sep 2024)
  
• Role of neuronal nicotinic acetylcholine receptors in cannabinoid dependence ☆ (29 Aug 2024)
  
• The endocannabinoid systemʼs involvement in motor development relies on cannabinoid receptors, TRP channels, and Sonic Hedgehog signaling (28 Aug 2024)
  
• Role of Endo-opioid and Endo-cannabinoid Systems in Migraine and Medication-overuse Headache (28 Aug 2024)
  
• Microglial Cannabinoid CB2 Receptors in Pain Modulation (28 Aug 2024)
  
• Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases (28 Aug 2024)
  
• Therapeutic Use of Cannabis in Inflammatory Bowel Disease (27 Aug 2024)
  
• The Enteric Glia and Its Modulation by the Endocannabinoid System, a New Target for Cannabinoid-Based Nutraceuticals? (27 Aug 2024)
  
• Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer’s disease (27 Aug 2024)
  
• Cannabinoid CB1 receptors regulate salivation (25 Aug 2024)
  
• Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting (20 Aug 2024)
  
• Metabolic Consequences of Gestational Cannabinoid Exposure (20 Aug 2024)
  
• Epigenetic Regulation of Cannabinoid-Mediated Attenuation of Inflammation and Its Impact on the Use of Cannabinoids to Treat Autoimmune Diseases (20 Aug 2024)
  
• Characterization of Endocannabinoid System and Interleukin Profiles in Ovine AEC: Cannabinoid Receptors Type-1 and Type-2 as Key Effectors of Pro-Inflammatory Response (20 Aug 2024)
  
• Cannabinoid Therapeutics in Chronic Neuropathic Pain: From Animal Research to Human Treatment (20 Aug 2024)
  
• Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox (20 Aug 2024)
  
• Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment (20 Aug 2024)
  
• The Modulating Role of Sex and Anabolic-Androgenic Steroid Hormones in Cannabinoid Sensitivity (19 Aug 2024)
  
• Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System (19 Aug 2024)
  
• Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges (18 Aug 2024)
  
• Culture and cannabinoid receptor gene polymorphism interact to influence the perception of happiness (18 Aug 2024)
  
• Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use (24 May 2024)
  
• Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy (13 May 2024)